ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Actavis Acquires Auden Mckenzie

by Lisa M. Jarvis
February 2, 2015 | APPEARED IN VOLUME 93, ISSUE 5

Continuing its acquisition spree, Actavis will pay roughly $460 million to buy Auden Mckenzie, a generic drug firm headquartered in London. By adding about 175 generic and branded products to its portfolio, the deal puts Actavis in the lead in the U.K. generics market. Since 2012, when it merged with Watson Pharmaceuticals, Actavis has been aggressively establishing a position in specialty pharmaceuticals through a series of acquisitions. Subsequent deals included the $5 billion purchase of Warner Chilcott; $25 billion spent on Forest Laboratories; and, most recently, $66 billion paid for Allergan.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment